Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) — OmniSeq, Inc., a molecular diagnostics subsidiary of the…
Read More
Twitter Feed
7-13% of cases discussed at tumor board result in changed treatment recommendation - interpretation is challenge #pmls2017 @JournPrecMed
George Poste: Identifying responders & non-responders is absolutely fundamental opportunity for precision medicine #pmls2017 @JournPrecMed
Thanks to @permedcoalition for allowing our CEO Mark Gardner to share the vision around comprehensive immune profiling. #immunotherapy
To better system efficiency, @OmniSeq hypothesizes tumor microenvironment may ID who can benefit from #immunotherapy https://t.co/RzeGYBEXDF
Cancer deal inked by @LABCORP and @OmniSeq
https://t.co/CqPL99FLLX
MuB alone not enough: "Mutational load alone is not sufficient to predict #Immunotherapy response" - Rajarsi Mandal @sloan_kettering #ngdx17